Corvus Pharmaceuticals, Inc. (CRVS)

In November 2025, Corvus Pharmaceuticals provided a business update and reported Q3 2025 financial results. In January 2026, the company's shares more than doubled after announcing positive Phase 1 trial data for soquelitinib in atopic dermatitis and completed an upsized underwritten public offering, generating approximately $201.2 million in gross proceeds. Following these events, several Wall Street analysts raised their price targets and reiterated positive ratings for CRVS. In February 2026, Corvus Pharmaceuticals presented at the Oppenheimer 36th Annual Healthcare Life Sciences Conference. In March 2026, the company provided a business update and reported fourth quarter and full-year 2025 financial results. Over the last 12 months, the stock's price has increased significantly, but decreased in the past month.

As a clinical-stage biopharmaceutical company without commercialized products, Corvus Pharmaceuticals does not experience demand seasonality in the traditional sense. Its financial performance is driven by research and development activities and clinical trial progress. Securing future funding is critical for its operations.

Corvus Pharmaceuticals, Inc. (CRVS) is a clinical-stage biopharmaceutical company focused on developing novel therapies targeting proteins crucial for immune cell function, applicable in cancer and immune diseases. The company is pioneering ITK inhibition as a new approach to immunotherapy. Its lead product candidate, soquelitinib, is in clinical trials for T cell lymphomas, atopic dermatitis, and is being advanced for other indications. Other product candidates include ciforadenant, in Phase 2 trials for metastatic renal cell cancer, and mupadolimab, in Phase 1b trials for non-small cell lung cancer.

Corvus Pharmaceuticals is headquartered in South San Francisco, California, and primarily develops its product candidates in the United States. The company has a licensing agreement with Angel Pharmaceuticals for development and commercialization in Greater China.

Corvus Pharmaceuticals' reputation is tied to its clinical trial progress and scientific innovation. Positive Phase 1 clinical trial results for soquelitinib in atopic dermatitis and a successful public offering have bolstered its reputation. Continued progress in its clinical pipeline further solidifies its reputation. However, the company faces risks due to the volatility of its share price and reliance on external funding.

Corvus Pharmaceuticals has a diverse ownership structure, with retail investors and institutions holding significant portions. Hedge funds also own a percentage of the shares. Major institutional and individual owners include OrbiMed Advisors LLC, BlackRock, Inc., Vanguard Group Inc, Morgan Stanley, Adams Street Partners Llc, Point72 Asset Management, L.P., State Street Corp, MPM Oncology Impact Management LP, Vivo Capital, LLC, Geode Capital Management, Llc, Caduceus Private Investments V, L.P., and CEO Richard Miller.